Literature DB >> 30205835

Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock.

Solenn Remy1, Morgane Gossez2,3, Alexandre Belot4,5, Jack Hayman2, Aurelie Portefaix6, Fabienne Venet2,3, Etienne Javouhey1, Guillaume Monneret7,8,9.   

Abstract

Entities:  

Keywords:  Biomarker; Hemophagocytic lymphohistiocytosis; Immune response; Septic shock

Mesh:

Substances:

Year:  2018        PMID: 30205835      PMCID: PMC6131803          DOI: 10.1186/s13054-018-2146-2

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Clinical presentations of hemophagocytic lymphohistiocytosis (HLH) and septic shock share many similarities, including multiple organ dysfunction and overall clinical and biological symptoms. However, these life-threatening conditions require specific and opposing treatments. Currently, no single biomarker is available to differentiate septic shock from HLH at patient admission [1, 2]. HLH is classified as a primary (genetically inherited) or a secondary, i.e., induced by various inflammatory conditions (viral infections, autoimmune processes, lymphoid malignancies, or drug allergies), immune disorder. We report here the case of a young woman with febrile shock which proved to be a HLH caused by drug-induced hypersensitivity syndrome (DIHS). As septic shock was initially suspected, the patient benefited from broad immunological screening during the first week of evolution [3]. Strikingly, this revealed massively increased expression of monocyte human leukocyte antigen-DR (mHLA-DR) at 137,021 ABC (antibody bound per cell), even though expected values in septic shock are usually drastically decreased [3]. In addition, a positive response to increasing doses of corticosteroids was observed over time (Fig. 1). More precisely, while the patient’s mHLA-DR expression was measured at 137,021 ABC at admission, it decreased to 38,961 ABC after the introduction of corticosteroids (day 3). Following the reactivation of inflammatory processes (day 5), mHLA-DR rose again (66,829 ABC). Finally, mHLA-DR returned to a normal range after increasing corticosteroid doses (20,499 ABC, day 8). All clinical features are provided in Additional file 1.
Fig. 1

Time course of mHLA-DR in a HLH patient. Blue squares depict mHLA-DR values in the HLH patient. Red circles represent pediatric septic shock values [3]. Gray range represents interquartile range values obtained previously in healthy children [3]. *Corticosteroids introduced, receiving 2 mg/kg/day; **corticosteroid adjustment to 4 mg/kg/day

Time course of mHLA-DR in a HLH patient. Blue squares depict mHLA-DR values in the HLH patient. Red circles represent pediatric septic shock values [3]. Gray range represents interquartile range values obtained previously in healthy children [3]. *Corticosteroids introduced, receiving 2 mg/kg/day; **corticosteroid adjustment to 4 mg/kg/day In the present patient, the extremely increased inaugural mHLA-DR value (i.e., 137,021 ABC) helped to unequivocally exclude a diagnosis of septic shock. Indeed, in our experience (more than 600 septic shock patients monitored over several years), the vast majority of mHLA-DR values measured within the first 3 days after septic shock are reported to be < 30,000 ABC and mostly found below 10,000 ABC (normal values ranged from 15,000 to 40,000 ABC). This agrees with pathophysiology since HLH is secondary to overproduction of interferon-γ (IFN-γ), a cytokine known to be a strong inducer of mHLA-DR expression, whereas sepsis induces downregulation of mHLA-DR expression. In conclusion, mHLA-DR may discriminate septic shock from HLH at admission despite both situations with multiple organ dysfunction sharing very common clinical and biological features (e.g., sCD25, elevated ferritin levels) [4, 5]. This result obviously needs further assessment in various types of HLH. Upon confirmation, as these two deadly conditions (i.e., septic shock and HLH) would require opposing treatments, mHLA-DR may be of crucial help for clinicians regarding patients’ care and management. Additional online information. (DOCX 27 kb)
  5 in total

1.  Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.

Authors:  Holger Jon Møller; Søren K Moestrup; Nina Weis; Christian Wejse; Henrik Nielsen; Svend Stenvang Pedersen; Jørn Attermann; Ebba Nexø; Gitte Kronborg
Journal:  Crit Care Med       Date:  2006-10       Impact factor: 7.598

Review 2.  Similar but not the same: Differential diagnosis of HLH and sepsis.

Authors:  Rafał Machowicz; Gritta Janka; Wieslaw Wiktor-Jedrzejczak
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-23       Impact factor: 6.312

3.  Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation.

Authors:  Leticia Castillo; Joseph Carcillo
Journal:  Pediatr Crit Care Med       Date:  2009-05       Impact factor: 3.624

4.  Occurrence of marked sepsis-induced immunosuppression in pediatric septic shock: a pilot study.

Authors:  Solenn Remy; Karine Kolev-Descamps; Morgane Gossez; Fabienne Venet; Julie Demaret; Etienne Javouhey; Guillaume Monneret
Journal:  Ann Intensive Care       Date:  2018-03-13       Impact factor: 6.925

Review 5.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

  5 in total
  4 in total

1.  COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.

Authors:  Matthijs Kox; Tim Frenzel; Jeroen Schouten; Frank L van de Veerdonk; Hans J P M Koenen; Peter Pickkers
Journal:  Crit Care       Date:  2020-05-26       Impact factor: 9.097

2.  Elevated TNF-α Induces Thrombophagocytosis by Mononuclear Cells in ex vivo Whole-Blood Co-Culture with Dengue Virus.

Authors:  Rahmat Dani Satria; Ming-Kai Jhan; Chia-Ling Chen; Po-Chun Tseng; Yung-Ting Wang; Chiou-Feng Lin
Journal:  J Inflamm Res       Date:  2022-03-05

3.  Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children.

Authors:  Kenz Le Gouge; Samira Khaldi-Plassart; Rémi Pescarmona; Thierry Walzer; Encarnita Mariotti-Ferrandiz; Etienne Javouhey; Marion Moreews; Anne-Laure Mathieu; Christophe Malcus; Sophia Djebali; Alicia Bellomo; Olivier Dauwalder; Magali Perret; Marine Villard; Emilie Chopin; Isabelle Rouvet; Francois Vandenesh; Céline Dupieux; Robin Pouyau; Sonia Teyssedre; Margaux Guerder; Tiphaine Louazon; Anne Moulin-Zinsch; Marie Duperril; Hugues Patural; Lisa Giovannini-Chami; Aurélie Portefaix; Behrouz Kassai; Fabienne Venet; Guillaume Monneret; Christine Lombard; Hugues Flodrops; Jean-Marie De Guillebon; Fanny Bajolle; Valérie Launay; Paul Bastard; Shen-Ying Zhang; Valérie Dubois; Olivier Thaunat; Jean-Christophe Richard; Mehdi Mezidi; Omran Allatif; Kahina Saker; Marlène Dreux; Laurent Abel; Jean-Laurent Casanova; Jacqueline Marvel; Sophie Trouillet-Assant; David Klatzmann; Alexandre Belot
Journal:  Sci Immunol       Date:  2021-05-25

4.  Myeloid phenotypes in severe COVID-19 predict secondary infection and mortality: a pilot study.

Authors:  Clémence Marais; Caroline Claude; Nada Semaan; Ramy Charbel; Simon Barreault; Brendan Travert; Jean-Eudes Piloquet; Zoé Demailly; Luc Morin; Zied Merchaoui; Jean-Louis Teboul; Philippe Durand; Jordi Miatello; Pierre Tissières
Journal:  Ann Intensive Care       Date:  2021-07-14       Impact factor: 6.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.